Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...
Kyverna Therapeutics’ $319 Million Upsized IPO
Altisource Portfolio Solutions’ $20.125 Million Follow-On Public Equity Offering
Paul Hastings and NautaDutilh advised Altisource, and The NBD Group advised the underwriter. Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) announced its underwritten public offering of shares...